Sea Lane’s technology platforms provide various avenues for drug discovery. Our Surrobody™ Technology offers superior biological capabilities and IP advantages over other scaffold therapeutics. Our Human Antibody Libraries provide numerous, high quality antibody leads to any target.
Our business strategy is geared to provide early access to certain technology platform components, and also to utilize novel technology components to create an internal research and early clinical pipeline on our own. In doing so, we expect to reduce typical R&D expenses as well as reach higher inflection point values for our investors, while bringing innovative approaches to patients with life threatening diseases.